Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 1 20Phase 1/2 6Phase 3 1Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 49Tumor-Agnostic 3Lymphoid 2Thoracic 1NET 1Endocrine 1

Conditions

Vipoma 1Somatostatinoma 1Neuroendocrine Tumors 1Neoplasms 1Lung Neoplasms 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Pemetrexed 23Carboplatin 21Cisplatin 20pembrolizumab 15Docetaxel 14Paclitaxel 10Gemcitabine 8Drug Therapy 7Bevacizumab 7Gefitinib 5Radiotherapy 4Magnetic Resonance Spectroscopy 4Erlotinib Hydrochloride 4130-nm albumin-bound paclitaxel 4cemiplimab 3atezolizumab 3anlotinib 3Dexamethasone 3dexamethasone acetate 2dexamethasone 21-phosphate 2cobimetinib 2auricularum 2aumolertinib 2apatinib 2Vemurafenib 2Topotecan 2Temozolomide 2Surgical Procedures, Operative 2Standard of Care 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Oxaliplatin × Thoracic × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡